Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof

1. A compound of formula (AI):

or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof,

wherein:

ring A is an aryl or a heteroaryl;

R 1 is —C(O)R 7 ;

each R 2 is identical or different, and each is independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, nitro, cyano, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;

R 3 is selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, cycloalkyloxy, haloalkoxy, amino, nitro, cyano, hydroxy, hydroxyalkyl and alkylthio, wherein the alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl and alkylthio are each optionally substituted by one or more groups selected from the group consisting of deuterium, halogen, alkoxy, haloalkoxy, amino, nitro, cyano, hydroxy and hydroxyalkyl;

R 4 is selected from the group consisting of hydrogen, alkyl, alkoxy, haloalkyl, hydroxyalkyl, cycloalkyl, cycloalkyloxy, heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more R 9 groups;

each R 5 is identical or different, and each is independently selected from the group consisting of hydrogen, alkyl, alkoxy, oxo, halogen, haloalkyl, haloalkoxy, amino, nitro, cyano, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(O)R 8 , —C(O)OR 8 , —NHC(O)R 8 , —NHC(O)OR 8 , —NR 10 R 11 , —C(O)NR 10 R 11 , —CH 2 NHC(O)OR 8 , —CH 2 NR 10 R 11 , —C(O)OCH(R 10 )R 11 and —S(O) m R 8 , wherein the alkyl is optionally substituted by one or more groups selected from the group consisting of deuterium, halogen, alkoxy, haloalkoxy, amino, nitro, cyano, hydroxy, hydroxyalkyl, —NR 10 R 11 and —NHC(O)OR 8 ;

R 7 is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of hydrogen, deuterium, halogen, alkyl, alkoxy, haloalkoxy, amino, nitro, cyano, hydroxy, hydroxyalkyl, cycloalkyl, cycloalkyloxy, heterocyclyl, aryl and heteroaryl;

R 8 is selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxy, amino, cycloalkyl, heterocyclyl, aryl and heteroaryl;

R 9 is selected from the group consisting of hydrogen, deuterium, halogen, alkyl, alkoxy, haloalkyl, amino, nitro, cyano, hydroxy, hydroxyalkyl, cycloalkyl, cycloalkyloxy, heterocyclyl, aryl and heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of deuterium, halogen, alkyl, alkoxy, haloalkyl, amino, nitro, cyano, hydroxy, hydroxyalkyl, cycloalkyl, cycloalkyloxy, heterocyclyl, —NHC(O)R 12 and R 13 ;

R 10 and R 11 are identical or different, and each is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl, heterocyclyl, —C(O)OR 8 and —OC(O)OR 12 , wherein the cycloalkyl and heterocyclyl are each optionally substituted by one or more groups selected from the group consisting of deuterium, halogen, alkyl, alkoxy, haloalkyl, oxo, amino, nitro, cyano, hydroxy and hydroxyalkyl;

R 12 is selected from the group consisting of hydrogen, alkyl, alkoxy, haloalkyl, haloalkoxy, amino, cycloalkyl, heterocyclyl, aryl and heteroaryl;

R 13 is aryl or heteroaryl, wherein the aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of hydrogen, deuterium, halogen, alkyl, alkoxy, haloalkyl, amino, nitro, cyano, hydroxy, hydroxyalkyl, cycloalkyl, cycloalkyloxy and heterocyclyl;

n is 0, 1, 2, 3 or 4;

m is 0, 1 or 2; and

s is 0, 1, 2, 3 or 4.

2. The compound according to claim 1 , being a compound of formula (I):

or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof, or mixture thereof, or a pharmaceutically acceptable salt thereof,

wherein:

L 1 is alkylene, wherein the alkylene is optionally substituted by one or more halogens or deuteriums;

R 6 is selected from the group consisting of hydrogen, deuterium, halogen, alkyl, alkoxy, amino, nitro, cyano, hydroxy, hydroxyalkyl, cycloalkyl, cycloalkyloxy, heterocyclyl, aryl and heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of deuterium, halogen, alkyl, alkoxy, haloalkyl, amino, nitro, cyano, hydroxy, hydroxyalkyl, cycloalkyl, cycloalkyloxy, heterocyclyl, —NHC(O)R 12 and R 13 ;

R 12 is selected from the group consisting of hydrogen, alkyl, haloalkyl, amino, cycloalkyl, heterocyclyl, aryl and heteroaryl;

R 13 is aryl or heteroaryl, wherein the aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of hydrogen, deuterium, halogen, alkyl, alkoxy, haloalkyl, amino, nitro, cyano, hydroxy, hydroxyalkyl, cycloalkyl, cycloalkyloxy and heterocyclyl; and

ring A, R 1 ˜R 3 , R 5 , n and s are as defined in claim 1 .

3. The compound of according to claim 2 , being a compound of formula (Iaa):

or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof or mixture thereof, or a pharmaceutically acceptable salt thereof,

wherein:

ring A, L 1 , R 1 ˜R 3 , R 5 ˜R 6 , n and s are as defined in claim 2 .

4. The compound according to claim 1 , wherein

is selected from the group consisting of:

wherein R 5 and s are as defined in claim 1 .

5. The compound according to claim 2 , being a compound of formula (II):

or a tautomer, mesomer racemate enantiomer, diastereomer thereof or mixture thereof, or a pharmaceutically acceptable salt thereof,

wherein:

R 7 is selected from the group consisting of alkyl, cycloalkyl and haloalkyl, wherein the alkyl and cycloalkyl are each optionally substituted by one or more groups selected from the group consisting of deuterium, halogen, alkyl and cycloalkyl; and

L 1 , R 2 , R 3 , R 5 , R 6 and n are as defined in claim 2 .

6. The compound according to claim 1 , wherein each R 5 is identical or different, and each is independently selected from the group consisting of alkyl, alkoxy, oxo, halogen, haloalkyl, cyano, hydroxy, —C(O)OR 8 , —NHC(O)OR 8 , —C(O)NR 10 R 11 , —CH 2 NHC(O)OR 9 , —CH 2 NR 10 R 11 , —C(O)OCH(R 10 )R 11 and —S(O) m R 8 ; R 8 is selected from the group consisting of hydrogen, alkyl, hydroxy and amino; R 10 and R 11 are identical or different, and each is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl, heterocyclyl, —C(O)OR 8 and —OC(O)OR 12 , wherein the cycloalkyl and heterocyclyl are each optionally substituted by one or more groups selected from the group consisting of deuterium, halogen, alkyl, alkoxy, haloalkyl, oxo, amino, nitro, cyano, hydroxy and hydroxyalkyl; and R 12 is alkyl.

7. The compound of formula (AI) according to claim 1 , wherein R 1 is —C(O)R 7 ; R 7 is selected from the group consisting of alkyl, cycloalkyl and haloalkyl, wherein the alkyl and cycloalkyl are each optionally substituted by one or more groups selected from the group consisting of deuterium, halogen, alkyl and cycloalkyl.

8. The compound according to claim 2 , being a compound of formula (III):

or a tautomer, mesomer, racemate, enantiomer, diastereomer thereof or mixture thereof, or a pharmaceutically acceptable salt thereof,

wherein:

each R 5 is identical or different, and each is independently selected from the group consisting of alkyl, alkoxy, oxo, halogen, haloalkyl, cyano, hydroxy, —C(O)OR 8 , —NHC(O)OR 8 , —C(O)NR 10 R 11 , CH 2 NHC(O)OR 8 , —CH 2 NR 10 R 11 , —C(O)OCH(R 10 )R 11 and —S(O) m R 8 ; R 8 is selected from the group consisting of hydrogen, alkyl, hydroxy and amino; R 10 and R 11 are identical or different, and each is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl, heterocyclyl, —C(O)OR 8 and —OC(O)OR 12 , wherein the cycloalkyl and heterocyclyl are each optionally substituted by one or more groups selected from the group consisting of deuterium, halogen, alkyl, alkoxy, haloalkyl, oxo, amino, nitro, cyano, hydroxy and hydroxyalkyl; R 12 is alkyl;

R 7 is selected from the group consisting of alkyl, cycloalkyl and haloalkyl, wherein the alkyl and cycloalkyl are each optionally substituted by one or more groups selected from the group consisting of deuterium, halogen, alkyl and cycloalkyl; and

L 1 , R 2 , R 3 , R 6 and n are as defined in claim 2 .

9. The compound according to claim 8 , being a compound of formula (IV):

wherein:

L 1 , R 2 , R 3 , R 6 , R 7 and n are as defined in claim 8 .

10. The compound according to claim 1 , wherein R 2 is halogen; and n is 0, 1 or 2.

11. The compound according to claim 1 , wherein R 3 is alkoxy, wherein the alkoxy is optionally substituted by one or more deuteriums or halogens.

12. The compound according to claim 2 , wherein L 1 is —(CR 14 2 ) x —, x is an integer of 1, 2, 3, 4; or 4; R 14 is hydrogen or deuterium; R 6 is selected from the group consisting of hydrogen, deuterium, halogen, alkyl, alkoxy, cycloalkyl, cycloalkyloxy, heterocyclyl, aryl and heteroaryl; wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of deuterium, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, —NHC(O)R 12 and R 13 ; R 12 is alkyl or cycloalkyl; R 13 is aryl or heteroaryl, wherein the aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of deuterium, halogen, alkyl, alkoxy, haloalkyl, amino, nitro, cyano and hydroxy.

13. The compound according to claim 2 , wherein L 1 is —CH 2 — or —CD 2 -; R 6 is selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl; wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of deuterium, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, —NHC(O)R 12 and R 13 ; R 12 is alkyl or cycloalkyl; R 13 is aryl or heteroaryl, wherein the aryl and heteroaryl are each optionally substituted by one or more groups selected from the group consisting of deuterium, halogen, alkyl, alkoxy, haloalkyl, amino, nitro, cyano and hydroxy.

14. The compound according to claim 2 , wherein L 1 is —CH 2 CH 2 —; and R 6 is alkyl, alkoxy or cycloalkyloxy.

15. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

16. A process for preparing the compound of formula (AI) according to claim 1 , comprising:

condensing a compound of formula (AI-A) with a compound of formula (AI-B) or a hydrochloride thereof under an alkaline condition to obtain a condensation product, optionally hydrolyzing the condensation product under an alkaline condition to obtain compound of formula (AI);

wherein:

ring A, R 1 ˜R 5 , n and s are as defined in claim 1 .

17. A process for preparing the compound of formula (I) according to claim 2 , comprising:

condensing a compound of formula (I-A) with a compound of formula (AI-B) or a hydrochloride thereof under an alkaline condition to obtain a condensation product, optionally hydrolyzing the condensation product under an alkaline condition to obtain the compound of formula (I);

wherein:

ring A, L 1 , R 1 ˜R 3 , R 5 ˜R 6 , n and s are as defined in claim 2 .

18. A pharmaceutical composition comprising the compound according to claim 1 , and one or more pharmaceutically acceptable carriers, diluents or excipients.

19. A method for preventing and/or treating a factor XIa mediated disease, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition according to claim 18 .

20. A method for preventing and/or treating a cardiovascular and cerebrovascular disease, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition according to claim 18 .

21. A method for inhibiting factor XIa, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition according to claim 18 .